CAMBRIDGE, MA: Genzyme hired Cohn & Wolfe to provide global pre-launch communications for alemtuzumab, a multiple sclerosis drug that received fast-track status from the Food and Drug Administration in June.
The drug is already approved to treat a form of leukemia. John Lacey, associate director of corporate communications at Genzyme, confirmed Cohn & Wolfe had won the account.
Mike Kan, global healthcare practice leader, and Lisa Talbot, EVP and co-director of the New York healthcare practice, are leading the account ...